School of Public Health, Xinxiang Medical University, Xinxiang, China.
State Key Laboratory of Applied Microbiology Southern China, Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Open Laboratory of Applied Microbiology, Institute of Microbiology, Guangdong Academy of Sciences, Guangzhou, China.
Microbiol Spectr. 2022 Aug 31;10(4):e0065722. doi: 10.1128/spectrum.00657-22. Epub 2022 Jun 22.
Inflammatory bowel disease (IBD) has become a global public health problem. Although the pathogenesis of the disease is unknown, a potential association between the gut microbiota and inflammatory signatures has been established. Probiotics, especially or , are orally taken as food supplements or microbial drugs by patients with IBD or gastrointestinal disorders due to their safety, efficacy, and power to restore the gut microenvironment. In the current study, we investigated the comprehensive effects of probiotic bacterial consortia consisting of Lactobacillus reuteri, Lactobacillus gasseri, Lactobacillus acidophilus ( spp.), and Bifidobacterium lactis ( spp.) or their metabolites in a dextran sodium sulfate (DSS)-induced colitis mouse model. Our data demonstrate that probiotic consortia not only ameliorate the disease phenotype but also restore the composition and structure of the gut microbiota. Moreover, the effect of probiotic consortia is better than that of any single probiotic strain. The results also demonstrate that mixed fermentation metabolites are capable of ameliorating the symptoms of gut inflammation. However, the administration of metabolites is not as effective as probiotic consortia with respect to phenotypic characteristics, such as body weight, disease activity index (DAI), and histological score. In addition, mixed metabolites led only to changes in intestinal flora composition. In summary, probiotic consortia and metabolites could exert protective roles in the DSS-induced colitis mouse model by reducing inflammation and regulating microbial dysbiosis. These findings from the current study provide support for the development of probiotic-based microbial products as an alternative therapeutic strategy for IBD. IBD is a chronic nonspecific inflammatory disease. IBD is characterized by a wide range of lesions, often involving the entire colon, and is characterized mainly by ulcers and erosions of the colonic mucosa. In the present study, we investigated the efficacy of probiotics on the recovery of gut inflammation and the restoration of gut microecology. We demonstrate that probiotic consortia have a superior effect in inhibiting inflammation and accelerating recovery compared with the effects observed in the control group or groups administered with a single strain. These results support the utilization of probiotic consortia as an alternative therapeutic approach to treat IBD.
炎症性肠病（IBD）已成为全球性公共卫生问题。尽管该疾病的发病机制尚不清楚，但已确定肠道微生物群与炎症特征之间存在潜在关联。由于安全性、疗效和恢复肠道微环境的能力，益生菌，特别是 或 ，被 IBD 或胃肠道疾病患者口服作为食品补充剂或微生物药物。在目前的研究中，我们调查了由罗伊氏乳杆菌、加氏乳杆菌、嗜酸乳杆菌（ spp.）和乳双歧杆菌（ spp.）组成的益生菌细菌联合体或其代谢物在葡聚糖硫酸钠（DSS）诱导的结肠炎小鼠模型中的综合作用。我们的数据表明，益生菌联合体不仅改善了疾病表型，而且还恢复了肠道微生物群的组成和结构。此外，益生菌联合体的效果优于任何单一益生菌菌株。结果还表明，混合发酵代谢物能够改善肠道炎症症状。然而，与益生菌联合体相比，代谢物的给药在体重、疾病活动指数（DAI）和组织学评分等表型特征方面的效果并不理想。此外，混合代谢物仅导致肠道菌群组成的变化。总之，益生菌联合体和代谢物通过减轻炎症和调节微生物失调在 DSS 诱导的结肠炎小鼠模型中发挥保护作用。本研究结果为开发基于益生菌的微生物产品作为 IBD 的替代治疗策略提供了支持。
IBD 是一种慢性非特异性炎症性疾病。IBD 的病变范围广泛，常累及整个结肠，主要表现为结肠黏膜溃疡和糜烂。在本研究中，我们研究了益生菌对肠道炎症恢复和肠道微生态恢复的疗效。我们证明，与对照组或单一菌株给药组相比，益生菌联合体在抑制炎症和加速恢复方面具有更好的效果。这些结果支持使用益生菌联合体作为治疗 IBD 的替代治疗方法。
